• Register
  • Login

European Journal of Molecular & Clinical Medicine

  1. Home
  2. A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

Journal Metrics

News

A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19

    Authors

    • Dr.Elayakumar S.T 1
    • Dr. Anbumalar M 2

    1 Senior Resident, Meenakshi Academy of Higher Education and Research

    2 Assistant Professor, Meenakshi Academy of Higher Education and Research

,

Document Type : Research Article

  • Article Information
  • Download
  • Export Citation
  • Statistics
  • Share

Abstract

Although a viral infection begins in COVID-19, some patients have overly exuberant inflammation, leading to acute pulmonary injury and a condition of adult respiratory distress (ARDS). As IL-6 is a key role in the inflammatory response, in this single centre observatory study in all Covid-19 patients with a proven SARS-CoV-2 fast-pacing infection in order to escape ALI and ARDS we have assessed the effectiveness and protection of tocilizumab (TCZ). In this single centre The rate of mortality in 104 patients treated for COVID-19 was lower (5 · 8%). The percentage of patients treated with COVID-19 was 11% lower than in untreated patients who had our level of treatment alone and a marginally lower rate of mortality (6 percent ). The acute phase reagents, Ferritin, and liver protein releases were quickly diminished by TCZ. Slowly, D-Dimer declined. Relevant safety issues were not found. An early prescribing of IL6-R antagonists can be safe and successful for avoidance, ICU admission and more complications in COVID-19 patients with imminent hyperinflammatory reaction1.

Keywords

  • COVID_19
  • Tocilizumab
  • pandemic
  • treatment
  • XML
  • PDF 213.71 K
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
    • Article View: 226
    • PDF Download: 344
European Journal of Molecular & Clinical Medicine
Volume 7, Issue 7
November 2020
Page 5752-5757
Files
  • XML
  • PDF 213.71 K
Share
Export Citation
  • RIS
  • EndNote
  • Mendeley
  • BibTeX
  • APA
  • MLA
  • HARVARD
  • VANCOUVER
Statistics
  • Article View: 226
  • PDF Download: 344

APA

S.T, D., & M, D. A. (2020). A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19. European Journal of Molecular & Clinical Medicine, 7(7), 5752-5757.

MLA

Dr.Elayakumar S.T; Dr. Anbumalar M. "A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19". European Journal of Molecular & Clinical Medicine, 7, 7, 2020, 5752-5757.

HARVARD

S.T, D., M, D. A. (2020). 'A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19', European Journal of Molecular & Clinical Medicine, 7(7), pp. 5752-5757.

VANCOUVER

S.T, D., M, D. A. A REVIEW ON USE OF TOCILIZUMAB FOR THE TREATMENT OF COVID-19. European Journal of Molecular & Clinical Medicine, 2020; 7(7): 5752-5757.

  • Home
  • About Journal
  • Editorial Board
  • Submit Manuscript
  • Contact Us
  • Glossary
  • Sitemap

News

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

Newsletter Subscription

Subscribe to the journal newsletter and receive the latest news and updates

© Journal Management System. Powered by ejournalplus